Dr. Fowler focused on developing groundbreaking new therapies for cancer patients and led the clinical research program for nearly ten years. He is considered one of the world's foremost experts in drug development for blood cancers, and his direct work led to the FDA approval of several novel agents in lymphoma. He also led development of one of the first combination immunotherapy regimens for untreated lymphomas, and is the primary investigator for the ongoing international phase III study with the combination.
Dr. Fowler has published over 150 articles in peer-reviewed journals as well as numerous textbooks on innovative approaches to cancer therapy. Prior to his work in medicine, Dr. Fowler served in the U.S. Army as a nuclear, biological and chemical defense specialist. In addition, he serves as the President and Founder of Halo House Foundation, a non-profit organization providing housing to blood cancer patients receiving treatment.